With an aging demographic all over the European Union, the European pharmaceutical sector is set to grow in the coming decades. Al-ready today the pharmaceutical industry is a key employer in Europe. At the same time, the pharmaceutical industry is marked by a very ex-pensive research and development phase, which makes strong intellectual property rights crucial to ensure that research for new pharmaceuticals remains commercially interesting. But not only direct threats to intellectual property rights, such as the production of generic phar-maceuticals or the sale of counterfeit pharmaceuticals, pose a threat to those pharmaceutical companies which heavily invest in research for the development of new products: different prices for identical pharmaceuticals in different member states of the European Community make it economically interesting to buy pharmaceuticals in one member state and sell them abroad. It might even be cheaper to sell reimported pharmaceuticals in the country of origin. This possibility opens a whole new market for reimporters which cuts directly into the profit of the producers. In this thesis we will look at different issues surrounding intellectual property rights in the European pharmaceutical sector by investigating the jurisprudence of the European Court of Justice and the Court of First Instance.
Table of Contents
1 INTRODUCTION
A. The importance of intellectual property rights in the pharmaceutical sector
B. Intellectual property rights as a challenge to the single market
C. Towards a Single Market in Pharmaceuticals
I. Introduction
II. The pharma industry and the pharma market in the EU
III. The pricing of pharmaceuticals
IV. Towards a single market in pharmaceuticals
V. The Frankfurt Round Tables and EU enlargement
D. Outline of the thesis
2 INTELLECTUAL PROPERTY RIGHTS AND FREE MOVEMENT OF GOODS
A. Intellectual property rights as a challenge to the free movement of goods
B. Existence and exercise of intellectual property rights
C. Exhaustion of rights
I. Introduction
II. Patents
1. Introduction
2. Exhaustion of patent rights trough marketing in another member state
3. Consensual marketing in other member states as a prerequisite for the exhaustion of patent rights
III. Trademarks
1. Exhaustion of trademark rights through marketing in another member state
2. Consensual marketing abroad as a requirement for the exhaustion of trademark rights
3. Repackaging and trademark rights
a) Consumer interests
b) Consumer confusion as a consideration for the ECJ
c) Limitations
d) Strategies
e) Artificial market segregation
f) Conclusions
4. Trademarks similar to but not connected with the protected trademark
IV. Copyright
D. Harmonization
I. Divergent domestic patent laws and the need for a European patent
II. Legislative developments
1. Directive 89/104
2. Regulation 40/94
3. Legal developments relating to copyright
4. Patentability of biotech products: directive 98/44
5. The directive on the enforcement of Intellectual Property Rights
E. Conclusions
3 INTELLECTUAL PROPERTY RIGHTS AND COMPETITION
A. Introduction
B. Again: existence and exercise of intellectual property rights
C. Intellectual property rights and Art. 81 EC Treaty
I. Introduction
II. Assignment
III. Licensing agreements
1. Applicability of Art. 81 EC Treaty to licensing agreements
2. Exemptions under Art. 81 (3) EC Treaty
IV. Technology transfer and other block exemptions
1. Technology transfer
2. Franchising
3. Other agreements
V. Other problems
D. Intellectual property rights and Art. 82 EC Treaty
I. Intellectual property rights as dominant positions
II. Abuse of a dominant position
1. Abuse of a dominant position through mergers and acquisitions (M&A)
2. High pricing and supply restrictions
a) Unfair pricing and Art. 82 EC Treaty
aa) Unfairly high pricing
bb) Unfairly low pricing
cc) Ties
dd) Discounts
ee) The relation between Art. 81 and Art. 82 EC Treaty
b) Supply decisions, the freedom to choose contracting partners and discriminatory pricing
aa) Discriminatory pricing
bb) Supply restrictions as abuse of a dominant position
cc) Limitations to the IP rightholders' right to choose contracting partners
E. Conclusions
4 NON-DISCRIMINATION
5 IP RIGHTS BETWEEN THE FREE MOVEMENT OF GOODS AND EC COMPETITION LAW
6 CONCLUSIONS
Research Objectives and Themes
The work examines the relationship between intellectual property rights and European law, focusing on how the European Court of Justice balances the protection of innovation with the principles of the Single Market and competition law within the pharmaceutical sector.
- Intellectual property rights as potential barriers to the free movement of goods.
- The concept of "exhaustion of rights" and its impact on parallel imports.
- Harmonization efforts in European patent, trademark, and copyright laws.
- Conflict between intellectual property rights and EC competition law, including abuse of dominant positions.
Excerpt from the Book
A. The importance of intellectual property rights in the pharmaceutical sector
In the pharmaceutical sector, what is today not more than an idea can soon be worth millions. It is therefore crucial to secure Intellectual Property (IP) Rights and for the inventor to be able to rely on the protection afforded by the law. Without the protection of the inventor's ideas there would be no incentive for the kind of innovation which is crucial in this industry. Furthermore can industrial secrets in the pharmaceutical sector not be kept all the way until a product is being marketed since new pharmaceuticals will have to pass numerous clinical trials and will be scrutinized prior to entering the market. Since new drugs cannot be kept out of sight from potential competitors for too long, pharmaceutical companies will have to act in time to ensure that their rights are being protected.
The timely protection of pharmaceutical intellectual property rights not only serves the company directly but also allows to create a intramural environment in which innovation is being rewarded. A pharmaceutical company which fails to reward ideas and inventions already before a profit is made with the product resulting from the ideas and inventions in question will soon find itself not only with less satisfied employees but also with less profit. Of the sums which have to be put into the entire research and development (R & D) phase, inventor benefits make up only a tiny fraction, yet one that is crucial for further innovation. Timely protection of intellectual property rights allows for timely rewards as well, fostering a culture of innovation among employees.
Summary of Chapters
1 INTRODUCTION: Discusses the necessity of intellectual property protection for driving pharmaceutical innovation and introduces the tensions between these rights and the European Single Market.
2 INTELLECTUAL PROPERTY RIGHTS AND FREE MOVEMENT OF GOODS: Explores how the ECJ resolves the conflict between national IP protection and the free movement of goods, specifically focusing on exhaustion of rights and repackaging.
3 INTELLECTUAL PROPERTY RIGHTS AND COMPETITION: Analyzes the interplay between IP rights and EC competition law, evaluating licensing agreements and the abuse of dominant market positions.
4 NON-DISCRIMINATION: Examines how the non-discrimination principle restricts the enforcement of patent rights when imported products face domestic market barriers.
5 IP RIGHTS BETWEEN THE FREE MOVEMENT OF GOODS AND EC COMPETITION LAW: Discusses the dual application of free movement and competition rules, concluding that both regimes operate simultaneously.
6 CONCLUSIONS: Summarizes that distinguishing between the existence and the exercise of an IP right is essential for balancing innovation and competition in the pharmaceutical industry.
Keywords
Intellectual Property, European Court of Justice, Single Market, Pharmaceutical Industry, Free Movement of Goods, Competition Law, Exhaustion of Rights, Patents, Trademarks, Copyright, Parallel Imports, Dominant Position, Repackaging, Innovation, Market Integration
Frequently Asked Questions
What is the fundamental topic of this work?
This work explores the legal tension between intellectual property rights and the European Union's principles of the free movement of goods and competition law, specifically within the pharmaceutical industry.
What are the primary thematic areas covered?
The analysis covers the exhaustion of intellectual property rights, the impact of national price fixing, the legitimacy of parallel imports, and the regulation of dominant market positions by pharmaceutical firms.
What is the core research objective?
The thesis aims to analyze how the European Court of Justice has historically balanced the protective nature of Intellectual Property law with the requirements of an open, competitive European Single Market.
Which scientific methods are utilized?
The study relies on a comprehensive analysis of the jurisprudence of the European Court of Justice and relevant European legislative developments regarding intellectual property.
What is addressed in the main part of the work?
The main body examines the specific limitations placed on patents, trademarks, and copyrights by the Single Market, as well as the application of Articles 81 and 82 of the EC Treaty to IP licensing and dominant firm behavior.
Which keywords characterize this work?
Key terms include Intellectual Property, European Single Market, Competition Law, Pharmaceutical Industry, ECJ Jurisprudence, Exhaustion of Rights, and Market Partitioning.
How does the author define the "specific subject matter" of IP rights?
The author refers to the ECJ's definition, describing it as the guarantee that the patentee or trademark owner can reward creative effort by exclusively putting products into circulation for the first time.
What does the "Hoffmann LaRoche-test" signify in this context?
It refers to the legal criteria established by the ECJ regarding the conditions under which a pharmaceutical product can be lawfully repackaged and imported without infringing upon trademark rights.
- Quote paper
- Rechtsanwalt Stefan Kirchner (Author), 2006, Pharmaceutical Intellectual Property Rights and the Single Market, Munich, GRIN Verlag, https://www.grin.com/document/137784
